Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemiaGrzegorz Helbig, Sławomira Kyrcz‐Krzemień, Alina Świderska et al.|Cancer Chemotherapy and Pharmacology|2011Cited by 24
Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1‐PDGFRA fusion transcript—results of Polish multicentre studyGrzegorz Helbig, Sławomira Kyrcz‐Krzemień, Andrzej Moskwa et al.|Hematological Oncology|2009Cited by 23